AAV transcytosis through barrier epithelia and endothelium

Трансцитоз AAV через барьерные эпителии и эндотелий
Giovanni Di Pasquale, John A. Chiorini
2005-12-22

AAV serotypesAAV transcytosisbarrier epitheliaendotheliumgene therapy
To transduce efficiently barrier epithelia such as the lung is the goal of several gene therapy applications. However, experiments with AAV-2 suggest that transduction is limited in this type of barrier epithelia. In contrast, other serotypes of AAV transduce barrier epithelia and exhibit broad dissemination throughout the tissue. Transcytosis is a process by which proteins and pathogens overcome barrier layers to reach the opposite cell surface. To understand better the entry pathway of AAV particles and their ability to penetrate barrier epithelia, we tested the hypothesis that the limited transduction of some barrier epithelia in vitro or the spread of some AAV serotypes through tissue in vivo is due to transcytosis. Our experiments demonstrate that dependoviruses can penetrate barrier cells by transcytosis. The process is rapid as well as serotype and cell-type specific and can be blocked by neutralizing antibodies, temperature, or chemical inhibitors of transcytosis. The particles isolated following apical-to-basolateral transport are still encapsulated and they can transduce permissive cell lines in vitro. Furthermore, the entry pathway used by AAV-5 for transcytosis appears to be independent of the one used for transduction. Importantly, inhibition of virus transcytosis results in a dramatic increase in intracellular vector and transduction.
1
AAV transcytosis is rapid and depends on both the viral serotype and the target cell type.
2
Blocking virus transcytosis markedly increases intracellular vector levels and transduction.
3
Dependoviruses, including AAV vectors, can cross barrier epithelial and endothelial cells through transcytosis.
4
For AAV-5, the transcytosis pathway appears distinct from the pathway mediating productive transduction.
5
Particles transported from the apical to basolateral surface remain encapsidated and retain infectivity for permissive cell lines.
6
Transcytosis can be blocked by neutralizing antibodies, low temperature, or chemical inhibitors of the process.

AAV particles, including different dependovirus serotypes, crossing barrier epithelial and endothelial cells

The serotype- and cell-type-specific transcytosis pathway of AAV particles, its regulation, and its relationship to intracellular vector accumulation and transduction

Publication Details
Publication Date
2005-12-22
Journal
Publisher
ISSN
Cited by
121
Access Type
Author Information
Authors
Giovanni Di Pasquale
John A. Chiorini
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%